期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 16, 页码 -出版社
MDPI
DOI: 10.3390/ijms23168991
关键词
mesothelioma; epigenetics; MicroRNA; microbiome; immune modulation; alternative splicing; asbestos; therapeutic targets
资金
- Department of Surgery, University of Pretoria
- South African Medical Research Council (SAMRC) [23108]
- National Research Foundation (NRF) [138139]
Malignant mesotheliomas are difficult-to-treat cancers with poor prognosis, particularly in Sub-Saharan African countries. Exposure to asbestos fibers and lack of regulatory frameworks contribute to the increasing burden of this disease. Epigenetic alterations induced by asbestos and microbiome-epigenetic interactions play crucial roles in the initiation and progression of malignant mesotheliomas. The potential use of epigenetic changes and microbiota as biomarkers and the advancement of combinatorial therapies are discussed for early detection and improved survival of patients.
Malignant mesotheliomas (MM) are hard to treat malignancies with poor prognosis and high mortality rates. This cancer is highly misdiagnosed in Sub-Saharan African countries. According to literature, the incidence of MM is likely to increase particularly in low-middle-income countries (LMICs). The burden of asbestos-induced diseases was estimated to be about 231,000 per annum. Lack of awareness and implementation of regulatory frameworks to control exposure to asbestos fibers contributes to the expected increase. Exposure to asbestos fibers can lead to cancer initiation by several mechanisms. Asbestos-induced epigenetic modifications of gene expression machinery and non-coding RNAs promote cancer initiation and progression. Furthermore, microbiome-epigenetic interactions control the innate and adaptive immunity causing exacerbation of cancer progression and therapeutic resistance. This review discusses epigenetic mechanisms with more focus on miRNAs and their interaction with the microbiome. The potential use of epigenetic alterations and microbiota as specific biomarkers to aid in the early detection and/or development of therapeutic targets is explored. The advancement of combinatorial therapies to prolong overall patient survival or possible eradication of MM especially if it is detected early is discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据